Recent SEC filings have disclosed that Jennifer Bush, who serves multiple roles at Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), sold a specific number of shares of common stock. Ms. Bush holds the titles of Chief Operating Officer, Chief Legal Officer, and Compliance Officer within the organization.
According to the filing details, on May 19, 2026, she divested 8,790 shares of Artiva Biotherapeutics common stock. These transactions accounted for a total value of $79,178.
The sale was executed at a weighted average price of $9.0078 per share. The individual transaction prices varied within a specific range, falling between $8.7439 and $9.0104. It is worth noting that the stock's current trading price has subsequently declined to $8.55. This represents an 18.6% drop observed over the course of the preceding week, although the company has demonstrated a substantial return of 296% when viewed over the past year.
Nature of the Stock Sales
Crucially, these sales were not discretionary. They were conducted under Artiva Biotherapeutics' established "sell-to-cover" policy. This policy is specifically designed to satisfy any required tax withholding obligations for the reporting person. The process was automatic and occurred in connection with the vesting and subsequent release of restricted stock units (RSUs).
Following the completion of these sales, Ms. Bush's direct ownership stake in Artiva Biotherapeutics common stock stands at 337,920 shares.
Company Developments and Clinical Progress
In separate corporate news, Artiva Biotherapeutics announced substantial developments regarding its AlloNK therapy. The company reported positive outcomes from a Phase 2a basket trial involving refractory rheumatoid arthritis patients. Specifically, the data indicated that 71% of these patients achieved an ACR50 response after at least six months of follow-up.
These clinical trial results are scheduled to be presented at the European Alliance of Associations for Rheumatology Congress. Furthermore, Artiva Biotherapeutics has undergone changes in its executive leadership structure. The company appointed Diego Miralles, M.D., as its new President and Head of Research and Development.
Dr. Miralles brings considerable experience to the role, having previously held leadership positions at both Laronde Inc. and Vividion Therapeutics, focusing on drug development. Following his appointment, the size of the board of directors was reduced from eight members to seven members.
Analyst Commentary and Valuation
From an analyst perspective, H.C. Wainwright increased its price target for Artiva Biotherapeutics to $35 while maintaining a Buy rating on the stock. The firm attributed this upward revision primarily to the positive trial outcomes observed in the rheumatoid arthritis data.
Regarding valuation, analysis provided by InvestingPro suggests that the company's stock currently appears overvalued when compared against its calculated Fair Value estimate. This platform also makes available 12 additional ProTips, intended to offer deeper insights into both the biotech firm’s financial standing and its overall market position.
Market Data Snapshot
The stock data provided shows the following recent activity:
- Current Price (Closed): $8.55
- Daily Change: Down $0.67 (-7.27%)
- After Hours Price: $8.78 (+2.69%)
The analysis period displayed ranged from 1 Day up to 5 Years, reflecting various timeframes for tracking the stock's performance.